Unannounced Foreign Drug Inspection Pilot, Other US Inspection Measures Enacted
Executive Summary
A suite of pharmaceutical inspection measures stripped from the user fee renewal legislation were added to the US FY 2023 spending law, including provisions for new inspection priorities, remote alternatives, mutual reliance, internal FDA coordination and unannounced foreign inspections.
You may also be interested in...
Congress Gives US FDA Austere Budget But Seeks Boosts On Inspections, IT, And ALS Activities
The minor cut would be masked by user fee revenue increases, but still would be the first time in at least a decade that agency's budget authority has dropped.
US FDA To Increase Surveillance Of Pharmaceutical Manufacturing Sites In Poor-Quality Countries
Agency revises internal guidance to incorporate statutory requirement for greater scrutiny of drug manufacturing facilities in countries where past experience demonstrates overall quality is low. Revised MAPP also allows for inspection deferral at sites that have superior quality systems.
US FDA To Increase Surveillance Of Pharmaceutical Manufacturing Sites In Poor-Quality Countries
Agency revises internal guidance to incorporate statutory requirement for greater scrutiny of drug manufacturing facilities in countries where past experience demonstrates overall quality is low. Revised MAPP also allows for inspection deferral at sites that have superior quality systems.